A novel arrangement for an electro-Fenton reactor aimed to treat neutral wastewater is presented. The arrangement consists on three-compartments in series, two of them packed with a cation exchange resin and one positioned between these, containing a polarized activated carbon column where the electrochemical generation of the Fenton reagent takes place. While the hydroxyl radicals electrochemically produced in-situ, react with the pollutant species adsorbed on the activated carbon cathode, the resin compartments administrate and collect the iron cation and the hydrated proton species in alternating flow direction cycles. The resulting process is a system that does not require acid or iron chemical addition to the process while at the same time, renders decontaminated water free of iron-dissolved species at neutral pH. The proposed electrochemical reactor arrangement is therefore the basis for the design of commercially viable electro-Fenton reactors in which the addition and subsequent removal of acid and iron chemicals is avoided; two of the currently most limiting features for the development of electro-Fenton technology for treating wastewater.

Background: The development of Multi-Target-Directed Ligands (MTDLs) has emerged as a significant strategy for addressing complex, overlapping pathologies such as cancer and Alzheimer’s disease (AD). This study aims to provide a robust computational framework for the design of dual-target inhibitors. Methods: This study presents an integrated and rigorous computational pipeline combining Quantitative Structure–Activity Relationship (QSAR) modeling, Molecular Docking, and Molecular Dynamics (MD) simulations with Dynamic Cross-Correlation Matrix (DCCM) analysis. Using a dataset of 57 known tubulin inhibitors, two high-performing QSAR models were developed to guide the rational design of 16 novel trimethoxyphenyl-based analogues. Results: Following ADMET and drug-likeness filtering, Lead Candidates 15 and 16 were identified. Quantitative activity predictions confirmed their enhanced potency thresholds, which were subsequently validated through static docking against β-tubulin (PDB: 4O2B) and Acetylcholinesterase (PDB: 1EVE). In total, 100 ns MD simulations and MM-GBSA calculations demonstrated superior binding stability and energetically favorable profiles for both targets, while DCCM analysis confirmed the functional synchrony of the protein–ligand complexes. Conclusions: The results provide a validated structural hypothesis for dual-target inhibition. The identified leads, 15 and 16, demonstrate strong predictive potential and are prioritized for chemical synthesis and in vitro biological evaluation.

Twelve novel triazole-based acetophenone derivatives (3a–3f, 4a–4f) synthesized via catalyst-free cycloaddition integrate a CYP121 inhibiting scaffold with dual anti-tubercular and antioxidant properties.

Implant-associated infections remain a major challenge in bone-related biomedical applications, where bacterial colonization and biofilm formation can compromise tissue integration and clinical performance. This study reports the mechanochemical synthesis, physicochemical characterization, antimicrobial activity, antibiofilm performance, and short-term fibroblast cytocompatibility of a TiO₂-containing bovine-derived biogenic hydroxyapatite ceramic composite (BHAp-TiO₂). The composite was prepared by high-energy mechanical milling using 10 wt% TiO₂ and characterized by X-ray diffraction, Rietveld refinement, Raman spectroscopy, Fourier-transform infrared spectroscopy, scanning electron microscopy, and energy-dispersive X-ray spectroscopy. XRD/Rietveld analysis identified a multiphase ceramic composite composed of hydroxyapatite, whitlockite, and rutile TiO₂, with no evidence of Ti⁴⁺ substitution into the hydroxyapatite lattice or detectable anatase within the XRD/Rietveld detection limit. SEM-EDS confirmed the granular agglomerated morphology of the powders and the elemental presence of Ti in BHAp-TiO₂. Compared with pristine BHAp, BHAp-TiO₂ produced a concentration-dependent reduction in AlamarBlue^®-derived bacterial metabolic activity against five clinically relevant planktonic strains. At 200 µg/mL, residual metabolic activity decreased to 10.90–32.90%, depending on the bacterial species, with the strongest response observed for Escherichia coli. In crystal violet assays, BHAp-TiO₂ markedly inhibited Pseudomonas aeruginosa biofilm biomass, reaching 91.9 ± 3.4% inhibition at 200 µg/mL. In NIH/3T3 fibroblasts, BHAp-TiO₂ preserved short-term cytocompatibility after 24 h of direct exposure within the 0.1–100 µg/mL range, with MTT- and AlamarBlue^®-derived responses remaining close to or above the 80% cytotoxicity limit. Overall, BHAp-TiO₂ is best interpreted as a rutile TiO₂-containing biogenic calcium phosphate ceramic composite with enhanced antimicrobial and antibiofilm performance while maintaining short-term fibroblast cytocompatibility under the evaluated conditions.